Advanced search
Publication Cover
Renal Failure Volume 45, 2023 - Issue 1
Submit an article Journal homepage
2,811
Views
0
CrossRef citations to date
0
Altmetric
Clinical Study

Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial

Xin-Yi Gaoa Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, ChinaView further author information
,
Yue-Ming Liua Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, ChinaView further author information
,
Dan-Na Zhenga Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, ChinaView further author information
,
Yi-Wen Lia Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, ChinaView further author information
,
Hua Lib Department of Nephrology, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaView further author information
,
Xiao-Ling Xiongb Department of Nephrology, Sir Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaView further author information
,
Hong-Yu Chenc Department of Nephrology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, ChinaView further author information
,
Hua Wangc Department of Nephrology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, ChinaView further author information
,
Xiao-Yong Yud Department of Nephrology, Shaanxi Traditional Chinese Medicine Hospital, Xi’an, ChinaView further author information
,
Kai Qud Department of Nephrology, Shaanxi Traditional Chinese Medicine Hospital, Xi’an, ChinaView further author information
,
Juan Jina Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, ChinaCorrespondence[email protected]
View further author information
,
Bo Lina Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, ChinaCorrespondence[email protected]
View further author information
&
Qiang Hee Department of Nephrology, First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3811-8226View further author information
ORCID Icon show all
Article: 2163505 | Received 17 Oct 2022, Accepted 22 Dec 2022, Published online: 13 Jan 2023

References

  • Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.
  • Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397–407.
  • Llach F. Hypercoagulability,renal vein thrombosis,and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985;28(3):429–439.
  • Rabelink TJ, Zwaginga JJ, Koomans HA, et al. Thrombosis and hemostasis in renal disease. Kidney Int. 1994;46(2):287–296.
  • Bennett A, Cameron JS. Platelet hyperaggregability in the nephrotic syndrome which is not dependent on arachidonic acid metabolism or on plasma albumin concentration. Clin Nephrol. 1987;27(4):182–188.
  • Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature. Eur J Haematol. 2019;102(4):312–318.
  • Robertson L, Yeoh SE, Ramli A. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Cochrane Database Syst Rev. 2017;12(12):CD011088.
  • Lee JY, Sung KC, Choi HI. Comparison of aspirin and indobufen in healthy volunteers. Platelets. 2016;27(2):105–109.
  • Vinazzer H, Fuccella LM. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation. J Clin Pharmacol. 1980;20(5-6 Pt 1):316–325.
  • D'Addato M, Curti T, Bertini D, et al. Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. Int Angiol. 1992;11(2):106–112.
  • Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation. 1993;87(1):162–164.
  • Huo J, Li M, Liu B, et al. A comparison of indobufen and low-molecular-weight heparin in the prevention of deep vein thrombosis in patients after total hip arthroplasty: a prospective randomized controlled study. Int J Clin Exp Med. 2019;12(3):2720–2728.
  • Lou X, Jin J, Gong J, et al. Comparison of the effects of indobufen and warfarin in a rat model of adenine-induced chronic kidney disease. Med Sci Monit. 2019;25:3566–3572.
  • Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11(1):1–8.
  • Gordon-Cappitelli J, Choi MJ. Prophylactic anticoagulation in adult patients with nephrotic syndrome. Clin J Am Soc Nephrol. 2020;15(1):123–125.
  • Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43(3):531–537.
  • Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775.
  • Pirmohamed M. Warfarin: the end or the end of one size fits all therapy? JPM. 2018;8(3):22.
  • Mohan A, Wanat MA, Abughosh SM. Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: a systematic review. Expert Rev Cardiovasc Ther. 2019;17(6):427–434.
  • Hofstra JM, Wetzels JFM. Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? Kidney Int. 2016;89(5):981–983.
  • Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.
  • Lensing AW, Prandoni P, Prins MH, et al. Deep-vein thrombosis. Lancet. 1999;353(9151):479–485.
  • Fowkes FJI, Price JF, Fowkes FGR. Incidence of DVT diagnosis deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25(1):1–5.
  • Borghi B, Casati A. Thromboembolic complications after total hip replacement. Int Orthop. 2002;26(1):44–47.
  • Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190–195.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.